Background
Acute coronary syndrome (ACS) is responsible for high rates of hospital
admission and readmission, which are associated with increased costs for the
patient and the health system, and increased in-hospital mortality
rates.
Objective
To evaluate readmission in patients with ACS and its determinants.
Methods
This was a retrospective cohort study of adult and elderly patients with ACS,
readmitted to public and private referral cardiology hospitals within one
year after the first hospitalization for ACS. The occurrence of
readmissions, the time elapsed from the first to the second admission, and
the use of medications at admission were collected from the medical records.
Associations between categorical variables were evaluated by the chi-square
test or the Fisher's exact test. Multiple logistic regression was used to
evaluate predictors for readmissions. A p < 0.05 was set as statistically
significant.
Results
Readmission rate was 21.5% (n = 115) and mean time between admissions was
122.7 ± 112.1 days. The patients were mostly men (64.0%), mean age of
63.15 ± 12.3 years. Among readmitted patients, 7% had a prognosis of
"death", and 68.7% were readmitted more than once within a one-year period.
The main reasons of readmission were cardiovascular diseases including ACS.
Private health care and the diagnosis of congestive heart failure were
associated with multiple logistic regression.
Conclusion
ACS was the main cause of readmission, with higher prevalence among users of
supplemental health care. Readmissions were associated with previous
diagnosis of congestive heart failure and the type of health care
provided.
Background: From a mechanistic standpoint, obstructive sleep apnea (OSA) may further disturb cardiovascular homeostasis in the setting of acute coronary syndrome (ACS).
BackgroundSystemic Arterial Hypertension (SAH) is one of the main risk factors for Coronary
Artery Disease (CAD), in addition to male gender. Differences in coronary artery
lesions between hypertensive and normotensive individuals of both genders at the
Coronary Computed Tomography Angiography (CCTA) have not been clearly
determined.ObjectiveTo Investigate the calcium score (CS), CAD extent and characteristics of coronary
plaques at CCTA in men and women with and without SAH.MethodsProspective cross-sectional study of 509 patients undergoing CCTA for CAD
diagnosis and risk stratification, from November 2011 to December 2012, at
Instituto de Cardiologia Dante Pazzanese. Individuals were stratified according to
gender and subdivided according to the presence (HT +) or absence (HT-) of
SAH.ResultsHT+ women were older (62.3 ± 10.2 vs 57.8 ± 12.8, p = 0.01). As for
the assessment of CAD extent, the HT+ individuals of both genders had significant
CAD, although multivessel disease is more frequent in HT + men. The regression
analysis for significant CAD showed that age and male gender were the determinant
factors of multivessel disease and CS ≥ 100. Plaque type analysis showed
that SAH was a predictive risk factor for partially calcified plaques (OR =
3.9).ConclusionHypertensive men had multivessel disease more often than women. Male gender was a
determinant factor of significant CAD, multivessel disease, CS ≥ 100 and
calcified and partially calcified plaques, whereas SAH was predictive of partially
calcified plaques.
Differential diagnosis between pre- and postcapillary pulmonary hypertension (PH) in patients with diastolic heart failure (DHF) is a challenge in clinical practice. The presence of PH is implicated in worse prognosis in patients with this disease. This case report approaches the process of investigation of pulmonary hypertension in adult patient with DHF, double mitral lesion, and sarcoidosis with poor clinical outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.